Avalo Therapeutics (AVTX) Income towards Parent Company (2014 - 2026)
Avalo Therapeutics (AVTX) posted Income towards Parent Company of -$19.6 million for Q1 2026, down 43.08% on a QoQ basis from -$13.7 million in Q4 2025, and down 49.29% year-over-year from -$38.7 million in Q1 2025.
Avalo Therapeutics (AVTX) Income towards Parent Company (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Income towards Parent Company history runs 12 years deep, the most recent figure standing at -$19.6 million for Q1 2026.
- Quarterly Income towards Parent Company fell 49.29% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.7 million (down 216.06% YoY) and the FY2025 annual result came in at -$78.3 million, down 122.78% from the prior year.
- Income towards Parent Company was -$19.6 million for Q1 2026 at Avalo Therapeutics, down from -$13.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $98.5 million in Q2 2024 and bottomed at -$121.3 million in Q1 2024.
- A 4-year average of -$12.7 million and a median of -$13.1 million in 2025 frame the typical range for Income towards Parent Company.
- Peak annual rise in Income towards Parent Company reached 1301.79% in 2024, while the deepest fall reached 1118.38% in 2024.
- Avalo Therapeutics' Income towards Parent Company stood at -$8.2 million in 2023, then tumbled by 332.65% to -$35.3 million in 2024, then jumped by 61.18% to -$13.7 million in 2025, then slumped by 43.08% to -$19.6 million in 2026.
- Business Quant data shows AVTX's Income towards Parent Company at -$19.6 million in Q1 2026, -$13.7 million in Q4 2025, and -$30.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Avalo Therapeutics | 395.30 Mn | 338.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | -13.72 Mn |
| Sep 30, 2025 | -30.63 Mn |
| Jun 30, 2025 | -20.77 Mn |
| Mar 31, 2025 | -13.15 Mn |
| Dec 31, 2024 | -35.34 Mn |
| Sep 30, 2024 | 23.04 Mn |
| Jun 30, 2024 | 98.46 Mn |
| Mar 31, 2024 | -121.29 Mn |
| Dec 31, 2023 | -8.17 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -9.96 Mn |
| Dec 31, 2021 | -65,000.00 |
| Sep 30, 2021 | 76,000.00 |
| Jun 30, 2021 | 69,000.00 |
| Mar 31, 2021 | -106,000.00 |
| Dec 31, 2020 | 499,000.00 |
| Sep 30, 2020 | -198,000.00 |
| Jun 30, 2020 | -455,000.00 |